News

This collaboration will enable Lundbeck’s researchers to take decisive steps towards new and better treatment of the debilitating and life-long brain disease that is schizophrenia. This joint project

Distinguished by a novel chimeric gene segment design, the Trianni platform provides Takeda with easy access to a complete human antibody repertoire that has been optimized for the

The 808 patent expires on 01 September 2015 and claims a process for manufacturing the active ingredient of the company’s relapsing-remitting multiple sclerosis (RRMS) product, Copaxone (glatiramer acetate

Hugel is the leading producer of anti-aging and Botulinum Toxin products in South Korea and Asia. Croma-Pharma managing director and owner Andreas Prinz noted that the company is

The application of Novozymes’ VELTIS technology in the drug delivers an extended half-life which will enable patients to inject only once per week. Novozymes business development executive vice

In the unanimous 14 – 0 decision, the AIDAC found that substantial evidence of the safety and effectiveness of SIVEXTRO for the treatment of acute bacterial skin and

The joint research facility will be located at AstraZeneca’s new research and development (R&D) center in Cambridge, scheduled to be completed in 2016. The AstraZeneca MRC UK Centre

The new vaccine will be manufactured at a newly-established facility at the company’s Hikari Plant in Hikari City, Yamaguchi Prefecture. In 2010, Takeda and Baxter International have entered

Alprolix is indicated for the control and prevention of bleeding episodes, perioperative (surgical) management and routine prophylaxis in adults and children with haemophilia B. The company said that